EUVIMEDEUVIMED entdecken
Crossref

Baseline Assessment of Serum Cytokines Predicts Clinical and Endoscopic Response to Ustekinumab in Patients With Crohn’s Disease: A Prospective Pilot Study

Lorenzo Bertani iD, Luca Antonioli, Marco Fornili, Vanessa D'Antongiovanni, Linda Ceccarelli, Luca Carmisciano, Laura Benvenuti, Maria Gloria Mumolo, Andrea Bottari, Veronica Pardi, Giovanni Baiano Svizzero, Laura Baglietto und 4 weitere

Inflammatory Bowel Diseases · 2024

DOI: 10.1093/ibd/izae133 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Inflammatory Bowel Diseases, 2024. Verfasst von Lorenzo Bertani und 15 weiteren Autor:innen. Beteiligte Einrichtung: University of Pisa, Department of Translational Research and New Technologies in Medicine and Surgery, Via Roma, 67, 56100 Pisa, Italy. Hauptthemen laut MEDLINE: Ustekinumab, Crohn Disease, Leukocyte L1 Antigen Complex, Biomarkers. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: Janssen Biotech spa.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

No biomarkers are currently available to predict therapeutic response to ustekinumab (UST) in Crohn’s disease (CD). The aim of this prospective study was to identify 1 or more cytokines able to predict mucosal healing in patients with CD treated with UST.

Methods

We prospectively enrolled consecutive CD patients treated with UST. At weeks 0 (baseline), 24, and 48, a panel of serum cytokines was measured by a fluorescence assay. At the same time points, fecal calprotectin (FC) was assessed. A colonoscopy was performed at baseline and at week 48, where therapeutic outcome was evaluated in terms of mucosal healing.

Results

Out of 44 patients enrolled, 22 (50%) achieved mucosal healing at the end of follow-up. Response was associated with higher interleukin (IL)-23 levels (P < .01). Fecal calprotectin levels decreased over time in responders but did not change in nonresponders (test for the interaction between time and mucosal healing, P < .001).

Conclusions

This pilot study showed that IL-23 and FC could be reliable biomarkers in predicting therapeutic outcome to UST therapy in CD. In particular, the correlation between baseline serum levels of IL-23 and mucosal healing at 48 weeks is particularly strong, paving the way for its use to drive therapeutic decisions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

UstekinumabCrohn DiseaseLeukocyte L1 Antigen ComplexBiomarkersFecesHumansPilot ProjectsFemaleMaleProspective StudiesAdultMiddle AgedIntestinal MucosaCytokinesColonoscopyInterleukin-23Treatment OutcomeYoung AdultFollow-Up Studies

Stichwörter der Autor:innen

Crohn’s diseasebiologicscytokinesmucosal healingustekinumab

Substanzen

UstekinumabLeukocyte L1 Antigen ComplexBiomarkersCytokinesInterleukin-23

Autor:innen und Institutionen

  • University of Pisa, Department of Translational Research and New Technologies in Medicine and Surgery, Via Roma, 67, 56100 Pisa, Italy.
  • Tuscany North West ASL, Department of General Surgery and Gastroenterology, Pontedera Hospital, Via Roma, 147, 56025, Pontedera, Italy.
  • University of Pisa, Department of Clinical and Experimental Medicine, Via Roma, 67, 56100, Pisa, Italy.
  • Pisa University Hospital, IBD Unit, Department of General Surgery and Gastroenterology, Via Paradisa, 2, 56124, Pisa, Italy.

ORCID-Profile: Lorenzo Bertani

Förderung

  • Janssen Biotech spa

Zitieren

APA

Bertani, L., Antonioli, L., Fornili, M., D'Antongiovanni, V., Ceccarelli, L., Carmisciano, L., Benvenuti, L., Mumolo, M. G., Bottari, A., Pardi, V., Baiano Svizzero, G., Baglietto, L., De Bortoli, N., Bellini, M., Fornai, M., & Costa, F. (2024). Baseline Assessment of Serum Cytokines Predicts Clinical and Endoscopic Response to Ustekinumab in Patients With Crohn’s Disease: A Prospective Pilot Study. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izae133

Vancouver

Bertani L, Antonioli L, Fornili M, D'Antongiovanni V, Ceccarelli L, Carmisciano L, et al. Baseline Assessment of Serum Cytokines Predicts Clinical and Endoscopic Response to Ustekinumab in Patients With Crohn’s Disease: A Prospective Pilot Study. Inflammatory Bowel Diseases. 2024. doi:10.1093/ibd/izae133

BibTeX
@article{Bertani2024,
  author = {Bertani, Lorenzo and Antonioli, Luca and Fornili, Marco and D'Antongiovanni, Vanessa and Ceccarelli, Linda and Carmisciano, Luca and Benvenuti, Laura and Mumolo, Maria Gloria and Bottari, Andrea and Pardi, Veronica and Baiano Svizzero, Giovanni and Baglietto, Laura and De Bortoli, Nicola and Bellini, Massimo and Fornai, Matteo and Costa, Francesco},
  title = {Baseline Assessment of Serum Cytokines Predicts Clinical and Endoscopic Response to Ustekinumab in Patients With Crohn’s Disease: A Prospective Pilot Study},
  journal = {Inflammatory Bowel Diseases},
  year = {2024},
  doi = {10.1093/ibd/izae133}
}
Kostenlos starten →